ReviewHuman vaccines & immunotherapeutics2014
Vaccines against invasive Salmonella disease: current status and future directions.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence of non-typhoidal Salmonella invasive disease: A systematic review and meta-analysis.The Journal of infection · 2021Pooled it
- Vaccines for preventing typhoid fever.The Cochrane database of systematic reviews · 2018Pooled it
- Critical Roles of O-Acetylation Revealed by Synthetic Trisaccharide Antigens for a Broad-Spectrum Anti-Salmonella Vaccine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SeaB is a conservedInfection and immunity · 2026Article
- Evaluating the Immunogenicity and Protective Efficacy of a Novel Vaccine Candidate AgainstVaccines · 2026Article
- Immunoinformatics-driven design of multi-epitope vaccine targeting antibiotic-resistant Salmonella typhimurium.PloS one · 2026Article
- HarnessingMaterials today. Bio · 2025Article
- Poultry Food Assess Risk Model forFoods (Basel, Switzerland) · 2025Article
- Synthesis and immunological evaluation of the lipopolysaccharide outer core ofChemical science · 2025Article
- Evasion of serum antibodies and complement by Salmonella Typhi and Paratyphi A.PLoS pathogens · 2025Article
- Assessing Salmonella Typhi Pathogenicity and Prevention: The Crucial Role of Vaccination in Combating Typhoid Fever.International journal of molecular sciences · 2025Review
- Salmonella Typhimurium derived OMV nanoparticle displaying mixed heterologous O-antigens confers immunogenicity and protection against STEC infections in mice.Microbial cell factories · 2025Article
- Evaluation of theFrontiers in bioengineering and biotechnology · 2025Article
- SHASI-ML: a machine learning-based approach for immunogenicity prediction inFrontiers in cellular and infection microbiology · 2025Article
- Foodborne Infections andVaccines · 2024Review
- Immunopeptidomics ofBiology · 2024Article
- Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.NPJ vaccines · 2024Review
- Unveiling a Comprehensive Multi-epitope Subunit Vaccine Strategy Against Salmonella subsp. enterica: Bridging Core, Subtractive Proteomics, and Immunoinformatics.Cell biochemistry and biophysics · 2024Article
- Salmonellosis: An Overview of Epidemiology, Pathogenesis, and Innovative Approaches to Mitigate the Antimicrobial Resistant Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though primarily enteric pathogens, Salmonellae are responsible for a considerable yet under-appreciated global burden of invasive disease. In South and South-East Asia, this manifests as enteric fever caused by serovars Typhi and Paratyphi A. In sub-Saharan Africa, a similar disease burden results from invasive nontyphoidal Salmonellae, principally serovars Typhimurium and Enteritidis. The existing Ty21a live-attenuated and Vi capsular polysaccharide vaccines target S. Typhi and are not effective in young children where the burden of invasive Salmonella disease is highest. After years of lack of investment in new Salmonella vaccines, recent times have seen increased interest in the area led by emerging-market manufacturers, global health vaccine institutes and academic partners. New glycoconjugate vaccines against S. Typhi are becoming available with similar vaccines against other invasive serovars in development. With other new vaccines under investigation, including live-attenuated, protein-based and GMMA vaccines, now is an exciting time for the Salmonella vaccine field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.